New WHO recommendations to prevent tuberculosis aim to save millions of lives

▴ New WHO recommendations to prevent tuberculosis aim to save millions of lives
TB preventive treatment is an affordable intervention that can prevent families from sliding into poverty and preserve the health and economy of whole communities. WHO anticipates new safer and cheaper drugs to bring down cost of treatment

New World Health Organization (WHO) guidance will help countries accelerate efforts to stop people with tuberculosis (TB) infection becoming sick with TB by giving them preventive treatment.

A quarter of the world‘s population is estimated to be infected with TB bacteria. These people are neither sick nor contagious. However, they are at greater risk of developing TB disease, especially those with weakened immunity. Offering them TB preventive treatment will not only protect them from becoming sick but also cut down on the risk of transmission in the community.  

As we mark World TB Day 2020, the disease remains the world’s top infectious killer. In 2018, 10 million people fell ill with TB worldwide and 1.5 million people lost their lives to this disease.

“COVID-19 is highlighting just how vulnerable people with lung diseases and weakened immune systems can be,“ said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “The world committed to end TB by 2030; improving prevention is key to making this happen. Millions of people need to be able to take TB preventive treatment to stop the onset of disease, avert suffering and save lives".

Dr Tedros highlighted the importance to continue efforts to tackle longstanding health problems, including TB during global outbreaks such as COVID-19. At the same time, programmes already in place to combat TB and other major infectious diseases can be leveraged to make the response to COVID-19 more effective and rapid.

Although some progress has been made towards targets set at the UN high-level Meeting on TB in 2018, TB preventive treatment has been largely neglected. Global leaders committed to ensuring access to TB preventive treatment to at least 24 million contacts of people with active TB and 6 million people living with HIV by 2022.  To date only a fraction of that target has been reached, with countries putting less than 430,000 contacts and 1.8 million people on TB preventive treatment in 2018.

TB remains the top cause of death among people with HIV. TB preventive treatment works synergistically with antiretroviral therapy to prevent TB and save lives. Reinvigorated efforts by governments, health services, partners, donors and civil society will be needed to increase access to TB preventive treatment to the levels targeted.

The new consolidated guidelines recommend a range of innovative approaches to scale up access to TB preventive treatment:

WHO recommends a scale-up of TB preventive treatment among populations at highest risk including household contacts of TB patients, people living with HIV and other people at risk with lowered” immunity or living in crowded settings. WHO recommends an integration of TB preventive treatment services into ongoing case finding efforts for active TB. All household contacts of TB patients and people living with HIV are recommended to be screened for active TB. If active TB is ruled out, they should be initiated on TB preventive treatment. WHO recommends that either a tuberculin skin test  or interferon-gamma release assay (IGRA) be used to test for TB infection. Both tests are helpful to find people more likely to benefit from TB preventive treatment but should not become a barrier to scale-up access. Testing for TB infection is not required before starting TB preventive treatment in people living with HIV, and children under 5 years who are contacts of people with active TB. WHO recommends new shorter options for preventive treatment in addition to the widely used 6 months of daily isoniazid. The shorter options that are now recommended range from a 1 month daily regimen of rifapentine plus isoniazid to 3 months weekly rifapentine plus isoniazid, 3 months daily rifampicin plus isoniazid, or 4 months of daily rifampicin alone.

“As people around the globe come together to commemorate World TB Day, WHO is calling on governments, affected communities, civil society organizations, health-care providers, donors, partners and the industry to unite forces and step up the TB response - notably for TB preventive treatment - to ensure no one is left behind,” said Dr Tereza Kasaeva, Director of WHO’s Global TB Programme. “The new WHO guidance shows the way forward for millions to rapidly access new tools and shorter, safer options for preventive treatment. The time for action is now.”

Tags : #Newregulations #Who #Tuberculosis

About the Author


Team Medicircle

Related Stories

13 Sep

Indegene Acquires DT Associates, Provides End-to-end Enterprise Solution for Customer Excellence - From Consulting to Operations

Indegene, a leading next-generation solutions organization for the Life Sciences industry globally, has entered into an agreement to acquire a majority stake in London-based DT Associates, a consulting company exclusively focused on helping pharmaceutical companies achieve excellence in Customer Experience (CX) and Digital Operations (DX). DT Associates will operate as a separate entity in Indegene Private Ltd, as 'DT Consulting' effective immediately.

View

-Advertisements-




Trending Now

1.5 Million Bottles Recalled: Is Your ADHD Medication Safe?March 03, 2025
Dressed for Trust: Why Doctors Must Wear White Aprons AgainMarch 03, 2025
India’s Pharma Revolution: Can New Regulatory Reforms Unleash a $42 Billion Industry?March 01, 2025
Pregnant and Pained: Is Paracetamol Poisoning Our Unborn Children?March 01, 2025
Are Your Idlis Poisoning You? The Hidden Dangers of Plastic in Indian KitchensMarch 01, 2025
Stuck in Slow Motion: How Bureaucracy is Choking India’s Pharma DreamFebruary 27, 2025
A New Spine, A New Life: Inside Kerala’s First 3D-Printed Titanium Cage SurgeryFebruary 27, 2025
India’s Newborns Are Dying from Sepsis And No One Is Talking About ItFebruary 27, 2025
Did the Government Force Covid Vaccines Without Responsibility? The Supreme Court Thinks SoFebruary 26, 2025
The Inequality of Survival: Why Some Women Die While Others LiveFebruary 26, 2025
The Corporate Invasion of Indian Hospitals: What It Means for YouFebruary 26, 2025
5 Simple Daily Habits to Keep Your Joints Healthy and Pain-FreeFebruary 25, 2025
Venus Remedies Secures Exclusive In-Licensing Rights from Infex Therapeutics to Develop and Commercialize MET-X in IndiaFebruary 25, 2025
With only 70 months left to end AIDS why is the urgency missing?February 25, 2025
Drenched in Oil: Is India Cooking Its Way to an Obesity Epidemic?February 25, 2025
Transforming Education: How Online Learning Platforms are Reshaping Study Material for Board and Competitive ExamsFebruary 24, 2025
February 24, 2025
The Dark Side of India’s Pharma Boom: How Banned Drugs Found a New Market in West AfricaFebruary 24, 2025
The Great Indian Medical Education Paradox: More Seats, Fewer Students, Collapsing SystemFebruary 24, 2025
From Science Fiction to Reality: AI Now Detects Blindness Before It StartsFebruary 24, 2025